Therapeutic targeting of TLR9 inhibits cell growth and induces apoptosis in neuroblastoma.

The Toll-like receptor 9 (TLR9) evolved to cope with pathogens, but it is expressed in a variety of tumors for reasons that are unclear. In this study, we report that neuroblastoma (NB) cells express functional TLR9. Liposome-complexed CpG oligonucleotides inhibited the proliferation of TLR9-expressing NB cells and induced caspase-dependent apoptotic cell death. Inhibitory oligonucleotides (iODNs) abrogated these effects. RNA interference reduced TLR9 expression but not to the level where functional responses to CpG were abolished. Compared with free CpG, liposomal formulations of NB-targeted CpG (TL-CpG) significantly prolonged the survival of mice bearing NB tumor xenografts. While CpG alone lacked antitumor efficacy in NOD/SCID/IL2rg(-/-) mice, TL-CpG retained significant efficacy related to direct effects on tumor cells. TLR9 expression in primary human NB specimens was found to correlate inversely with disease stage. Our findings establish functional expression of TLR9 in NB and suggest that TLR9 may represent a novel theranostic target in this disease.

• Publication year

  2010

• Venue

  Cancer Research

• Publication date

  2010-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-10-1251PMID 20935225
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Down-Regulation of TLR9 Expression Affects the Maturation and Function of Murine Bone Marrow-Derived Dendritic Cells Induced by CpG

  2009cited by this paper
• Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists.

  2009cited by this paper
• Tumoricidal Effects of Activated Macrophages in a Mouse Model of Chronic Lymphocytic Leukemia1

  2009cited by this paper
• Anti-IL-10R antibody improves the therapeutic efficacy of targeted liposomal oligonucleotides.

  2009cited by this paper
• Significance of Toll-like Receptors Expression in Tumor Growth and Spreading: A Short Review

  2008cited by this paper
• Enhanced Antitumor Efficacy of Clinical-Grade Vasculature-Targeted Liposomal Doxorubicin

  2008cited by this paper
• The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor

  2008cited by this paper
• Combined Therapeutic Effects of Vinblastine and Rapamycin on Human Neuroblastoma Growth, Apoptosis, and Angiogenesis

  2007cited by this paper
• Functional expression of TLR9 is associated to the metastatic potential of human lung cancer cell

  2007cited by this paper
• Intracellular expression of toll-like receptor 4 in neuroblastoma cells and their unresponsiveness to lipopolysaccharide

  2006cited by this paper
• Therapeutic potential of Toll-like receptor 9 activation

  2006cited by this paper
• Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors

  2006cited by this paper
• Caspases 3 and 7: Key Mediators of Mitochondrial Events of Apoptosis

  2006cited by this paper
• RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system.

  2006cited by this paper
• Suppression of TNFalpha production in LPS induced liver failure in mice after intravenous injection of cationic liposomes/NFkappaB decoy complex.

  2006cited by this paper
• Experimental therapy of prostate cancer with an immunomodulatory oligonucleotide: Effects on tumor growth, apoptosis, proliferation, and potentiation of chemotherapy

  2006cited by this paper
• Monocyte/Macrophage Dysfunctions Do Not Impair the Promotion of Myelofibrosis by High Levels of Thrombopoietin1

  2006cited by this paper
• Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer.

  2006cited by this paper
• Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy.

  2006cited by this paper
• Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis.

  2006cited by this paper
• Toll-like receptors on tumor cells facilitate evasion of immune surveillance.

  2005cited by this paper
• The role of epithelial Toll-like receptor expression in host defense and microbial tolerance

  2005cited by this paper
• Toll-like receptor control of the adaptive immune responses

  2004cited by this paper
• TLR9 signals after translocating from the ER to CpG DNA in the lysosome

  2004cited by this paper
• Expression and subcellular distribution of toll‐like receptors TLR4, TLR5 and TLR9 on the gastric epithelium in Helicobacter pylori infection

  2004cited by this paper
• Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs.

  2004cited by this paper
• Bioavailability of antisense oligonucleotides in neuroblastoma cells: comparison of efficacy among different types of molecules

  2004cited by this paper
• Neuroblastoma: biological insights into a clinical enigma

  2003cited by this paper
• Repetitive Elements in Mammalian Telomeres Suppress Bacterial DNA-Induced Immune Activation1

  2003cited by this paper
• Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.

  2003cited by this paper
• Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs.

  2002cited by this paper
• Processing of gene expression data generated by quantitative real-time RT-PCR.

  2002cited by this paper
• Caspases are not localized in mitochondria during life or death

  2002cited by this paper
• Effect of Suppressive DNA on CpG-Induced Immune Activation1

  2002cited by this paper
• Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition

  2001cited by this paper
• A new liposomal formulation for antisense oligodeoxynucleotides with small size, high incorporation efficiency and good stability.

  2000cited by this paper
• Delivery of c-myb Antisense Oligodeoxynucleotides to Human Neuroblastoma Cells Via Disialoganglioside GD2-Targeted Immunoliposomes: Antitumor Effects.

  2000cited by this paper
• Delivery of c-myb antisense oligodeoxynucleotides to human neuroblastoma cells via disialoganglioside GD(2)-targeted immunoliposomes: antitumor effects.

  2000cited by this paper
• Selecting optimal oligonucleotide composition for maximal antisense effect following streptolysin O-mediated delivery into human leukaemia cells.

  1998cited by this paper
• Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow.

  1997cited by this paper
• A metastatic neuroblastoma model in SCID mice

  1996cited by this paper
• Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation.

  1995cited by this paper
• A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas.

  1995cited by this paper
• Tetraplex folding of telomere sequences and the inclusion of adenine bases.

  1994cited by this paper
• Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment.

  1993cited by this paper
• Hematopoietic stem-cell defects underlying abnormal macrophage development and maturation in NOD/Lt mice: defective regulation of cytokine receptors and protein kinase C.

  1993cited by this paper
• Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

  1993cited by this paper
• Rate of internalization of an immunotoxin correlates with cytotoxic activity against human tumor cells.

  1989cited by this paper
• Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth.

  1987cited by this paper

• TLR9: A Double-Dealing Toll-Like Receptor

  2025cites this paper
• Discovery of Potent and Selective Quinoline-Based Toll-like Receptor 9 Antagonists.

  2025cites this paper
• TLR2 and TLR9 Blockade Using Specific Intrabodies Inhibits Inflammation-Mediated Pancreatic Cancer Cell Growth

  2024cites this paper
• Engineering nanoparticles for cancer immunotherapy: Current achievements, key considerations and future perspectives

  2024cites this paper
• Plasmacytoid dendritic cells mediate CpG-ODN induced increase in survival in a mouse model of lymphangioleiomyomatosis

  2023cites this paper
• Engineered CpG‐Loaded Nanorobots Drive Autophagy‐Mediated Immunity for TLR9‐Positive Cancer Therapy

  2023cites this paper
• Targeted immune activation in pediatric solid tumors: opportunities to complement local control approaches

  2023cites this paper
• Small-Molecule Modulators Targeting Toll-like Receptors for Potential Anticancer Therapeutics.

  2023cites this paper
• Toll-like receptor agonist combinations augment mouse T-cell anti-tumor immunity via IL-12- and interferon ß-mediated suppression of immune checkpoint receptor expression

  2022cites this paper
• Recent Advances in Cancer Vaccines: Challenges, Achievements, and Futuristic Prospects

  2022cites this paper
• Lipid-Based Delivery Systems in Development of Genetic and Subunit Vaccines

  2022cites this paper
• The role of toll-like receptors (TLRs) in pan-cancer

  2022cites this paper
• TLRs as a Promise Target Along With Immune Checkpoint Against Gastric Cancer

  2021cites this paper
• Tilsotolimod: an investigational synthetic toll-like receptor 9 (TLR9) agonist for the treatment of refractory solid tumors and melanoma

  2021cites this paper
• Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments

  2021cites this paper
• Toll-like receptors: Triggers of regulated cell death and promising targets for cancer therapy.

  2020cites this paper
• Toll-like Receptors from the Perspective of Cancer Treatment

  2020cites this paper
• Toll-like receptor-induced cytokines as immunotherapeutic targets in cancers and autoimmune diseases.

  2020cites this paper
• Nanomaterials as Smart Immunomodulator Delivery System for Enhanced Cancer Therapy.

  2020cites this paper
• Toll-like receptor (TLR) gene expression and immunostimulatory effect of CpG oligonucleotides in hormone receptor positive cell line T47D and triple negative breast cancer cell line MDA-MB-468

  2020cites this paper
• Cathelicidins Modulate TLR-Activation and Inflammation

  2020cites this paper
• Vaccines, Adjuvants, and Delivery Systems

  2019cites this paper
• Nucleic Acid Sensors and Programmed Cell Death

  2019cites this paper
• Machine learning and bioinformatics models to identify gene expression patterns of ovarian cancer associated with disease progression and mortality

  2019cites this paper
• Pharmacological modulation of nucleic acid sensors — therapeutic potential and persisting obstacles

  2019cites this paper
• CD93 is a cell surface lectin receptor involved in the control of the inflammatory response stimulated by exogenous DNA

  2019cites this paper
• Toll‐like receptors: A pathway alluding to cancer control

  2019cites this paper
• Targeting Toll-Like Receptors for Cancer Therapy

  2018cites this paper
• Toll-like receptor 9 activation by CpG oligodeoxynucleotide 7909 enhances the radiosensitivity of A 549 lung cancer cells via the p 53 signaling pathway

  2018cites this paper
• Extracellular DNA promotes colorectal tumor cell survival after cytotoxic chemotherapy.

  2018cites this paper
• Intratumoral CpG-B Promotes Antitumoral Neutrophil, cDC, and T-cell Cooperation without Reprograming Tolerogenic pDC.

  2018cites this paper
• Toll-like receptor 9 activation by CpG oligodeoxynucleotide 7909 enhances the radiosensitivity of A549 lung cancer cells via the p53 signaling pathway.

  2018cites this paper
• In ovo administration of Toll-like receptor ligands encapsulated in PLGA nanoparticles impede tumor development in chickens infected with Marek's disease virus.

  2018cites this paper
• Toll-like receptor stimulation in cancer: A pro- and anti-tumor double-edged sword.

  2017cites this paper
• Pattern recognition receptors: immune targets to enhance cancer immunotherapy

  2017cites this paper
• Rôle de TLR7 dans la progression tumorale dans le cancer du poumon

  2017influential citation
• Comparing the Expression Levels of Toll Like Receptors 2, 4 and, in Normal and Cancerous Tissues of Patients with Laryngeal Carcinoma

  2016cites this paper
• Vaccine adjuvants as potential cancer immunotherapeutics

  2016cites this paper
• Hybrid Cells Derived from Human Breast Cancer Cells and Human Breast Epithelial Cells Exhibit Differential TLR4 and TLR9 Signaling

  2016cites this paper
• Clients and Oncogenic Roles of Molecular Chaperone gp96/grp94.

  2016cites this paper
• TLR3 triggering regulates PD-L1 (CD274) expression in human neuroblastoma cells.

  2015cites this paper
• Phosphorothioate-modified CpG oligodeoxynucleotide (CpG ODN) induces apoptosis of human hepatocellular carcinoma cells independent of TLR9

  2014cites this paper
• Toll-Like Receptor 9 Agonists for Cancer Therapy

  2014influential citation
• Linking Obesity and Pancreatic Cancer

  2014cites this paper
• Phosphorothioate modification of the TLR9 ligand CpG ODN inhibits poly(I:C)-induced apoptosis of hepatocellular carcinoma by entry blockade.

  2014cites this paper
• Pattern Recognition Receptors and Aging

  2014cites this paper
• Liposomes as vaccine delivery systems: a review of the recent advances

  2014cites this paper
• Toll-like receptor 9 in alimentary tract cancers

  2014cites this paper
• The Yin and Yang of Toll-like receptors in cancer

  2014cites this paper
• Quantitative magnetic resonance imaging in the transgenic APC(Δ468) mouse model of hereditary colon cancer.

  2013cites this paper
• Toll-like receptor agonists: current status and future perspective on their utility as adjuvants in improving anticancer vaccination strategies.

  2013cites this paper
• Similar Gene Regulation Patterns for Growth Inhibition of Cancer Cells by RP215 or Anti-Antigen Receptors

  2013influential citation
• Pattern-recognition receptors and neutrophils in cancer inflammation

  2013cites this paper
• Enhanced anti-tumor and anti-angiogenic efficacy of a novel liposomal fenretinide on human neuroblastoma.

  2013cites this paper
• Impact of Tumor HER2/ERBB2 Expression Level on HER2-Targeted Liposomal Doxorubicin-Mediated Drug Delivery: Multiple Low-Affinity Interactions Lead to a Threshold Effect

  2013cites this paper
• Dual character of Toll-like receptor signaling: pro-tumorigenic effects and anti-tumor functions.

  2013cites this paper
• Small Interfering RNA Targeting Toll-Like Receptor 9 Protects Mice against Polymicrobial Septic Acute Kidney Injury

  2013cites this paper
• TLR agonists: our best frenemy in cancer immunotherapy

  2013cites this paper
• Cancer Vaccination, Will You Have To Pay The Toll?

  2013cites this paper
• Targeting pattern recognition receptors in cancer immunotherapy

  2012cites this paper
• Description of a new xenograft model of metastatic neuroblastoma using NOD/SCID/Il2rg null (NSG) mice.

  2012cites this paper
• Toll-Like Receptors as Novel Therapeutic Targets for the Treatment of Pancreatic Cancer

  2012cites this paper
• Roles of toll-like receptors in Cancer: A double-edged sword for defense and offense

  2012cites this paper
• Exogenous or endogenous Toll-like receptor ligands: which is the MVP in tumorigenesis?

  2012cites this paper
• Analysis of apoptosis methods recently used in Cancer Research and Cell Death & Disease publications

  2012cites this paper
• Toll-Like Receptors as Novel Therapeutic Targets for Ovarian Cancer

  2012cites this paper
• The elucidation of gene transferring mechanism by ultrasound-responsive unmodified and mannose-modified lipoplexes.

  2011cites this paper
• Absent Toll-like receptor-9 expression predicts poor prognosis in renal cell carcinoma

  2011cites this paper
• Advanced methodologies to formulate nanotheragnostic agents for combined drug delivery and imaging

  2011cites this paper
• Neuroblastoma therapy: what is in the pipeline?

  2011cites this paper